Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome - Episode 7

Data from the TELEPATH Trial and Real-World Analyses

October 4, 2022

Satya (Nanu) Das, MD, MSCI, Jerome Zacks, MD, Rodney Pommier, MD

Dr Pommier discusses key safety, efficacy, and quality of life data from the TELEPATH trial investigating the tryptophan hydroxylase inhibitor telotristat ethyl, while Dr Das comments on real-world data complements to the trial.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Neuroendocrine Tumors (NETs)

EP. 2: Overview of Carcinoid Syndrome (CS)

EP. 3: Overview of Carcinoid Heart Disease (CHD)

EP. 4: Management of Carcinoid Syndrome-Related Symptoms

EP. 5: Diagnosis and Management of Somatostatin Analog-Refractory Carcinoid Syndrome

EP. 6: Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome

Now Viewing

EP. 7: Data from the TELEPATH Trial and Real-World Analyses

EP. 8: Prevention, Treatment, and Management of Carcinoid Heart Disease

EP. 9: Unmet Needs for Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

EP. 10: Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome